Advertisement


Matteo Lambertini, MD, PhD, on Oncofertility Care for Young Women With Breast Cancer

ESMO Congress 2022

Advertisement

Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, talks about why oncofertility counseling should now be considered mandatory in the care of young women with breast cancer. Among the treatments he recommends offering are oocyte/embryo cryopreservation (or ovarian tissue cryopreservation in those not eligible for gamete cryopreservation); ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy; and long-term follow-up to improve the management of gynecology-related issues faced by these women.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Oncofertility care is a crucial component of cancer care in all patient diagnosed at reproductive years. It's clearly stated by all guidelines that we should discuss, we actually must discuss this topic with all newly diagnosed patient, irrespective type and stage of the disease. And oncofertility means discussing the so-called risk of gynotoxicity, the risk of developing in female cancer patient premature ovarian sufficiency. This risk is we know very well out to estimate this risk when we offer chemotherapy with standard chemotherapy agents. We know very well, according to patient age, as well as type of chemotherapy, what is the risk of gynotoxicity. This is the first step of the oncofertility counseling. After this step, and this is something that all medical oncologists should do to raise the issue and to then refer patient interest into fertility preservation strategies to fertility specialists, which is the second step of the oncofertility consult. In the second step, the fertility preservation strategies are being discussed. Among these strategies, the first and standard option is ooctye/embryo cryopreservation. This is the most important and the first of fertility preservation strategies to be discussed with all patient interest to increase their chances of a future pregnancy. A second option is of ovarian tissue cryopreservation, to be proposed to patient that are not eligible to ooctye/embryo cryopreservation for a variety of reasons. And finally, we have the possibility to use [inaudible 00:01:40] during chemotherapy. However, this last strategy is not per se a fertility preservation option, so it does not replace cryopreservation procedures, but should be considered only after cryopreservation procedures or to induce patients that are not interested in fertility preservation, but want to reduce the risk of premature ovarian insufficiency, so all the side effects of early menopause. [inaudible 00:02:02] oncofertility nowadays is not only fertility preservation strategies. I do believe that is something more than that. And with this concept of a kind of enlarged oncofertility care, we want also to include other important aspects for many patient in terms, for example, on how to manage the gynecological toxicity of anticancer treatment like adjuvant endocrine therapy and breast cancer patient, sexual dysfunction, menopause-rated symptoms. So all symptoms that as medical oncologists when we are not really well trained to manage and other important issues like contraception, pregnancy-related issues that are highly relevant to many patients. What is important for oncofertility care is really to build a network. A network between different specialists that will manage the different aspect of these oncofertility care. As medical oncologists, our responsibility is to raise the point of the gynotoxicity, the risk of developing this side effect, and then to build this network with gynecologist fertility specialists, the psychologists, expert in for example, sexual dysfunction, so that we can refer patient with the interest in these different aspects to a more experienced colleagues and physician. As the next step in this field, it's important to highlight that in the current era of, for example, genetic testing or new anticancer treatment, targeted therapies, antibody-drug conjugate, there are a lot of questions to be answered in the field, the risk of gynotoxicity of this new treatment, so the impact also on the ovarian function and ovarian reserve of our patient. These are question that we really need to address quite urgently in the coming month.

Related Videos

Kidney Cancer

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss results from two important trials presented at ESMO 2022: Cohort 1 of the LITESPARK-003 study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC), and the KEYNOTE-B61 study of pembrolizumab plus lenvatinib as first-line treatment for non–clear cell RCC (Abstracts 1447O and 1448O).

Pancreatic Cancer

Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel

Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).

Lung Cancer
Immunotherapy

Gérard Zalcman, MD, PhD, on Non–Small Cell Lung Cancer: Phase III Trial Findings on Nivolumab and Ipilimumab

Gérard Zalcman, MD, PhD, of France’s Bichat-Claude Bernard Hospital, Assistance Publique–Hôpitaux de Paris, discusses phase III results from the IFCT-1701 trial, which explored the questions of whether to administer nivolumab plus ipilimumab for 6 months or whether to prolong the treatment in patients with advanced non–small cell lung cancer (Abstract 972O).

Gynecologic Cancers

Ana Oaknin, MD, PhD, on Cervical Cancer: New Findings on Cemiplimab in Recurrent or Metastatic Disease

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses an analysis of long-term survival from the EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. Cemiplimab-rwlc is the first immunotherapy to demonstrate an overall survival benefit as a second-line monotherapy for patients with recurrent or metastatic cervical cancer previously treated with platinum-based chemotherapy but not immunotherapy. The benefit was sustained in this population (Abstract 519MO).

Skin Cancer

Neil D. Gross, MD, on Cutaneous Squamous Cell Carcinoma: Recent Findings on Cemiplimab

Neil D. Gross, MD, of The University of Texas MD Anderson Cancer Center, discusses data from a phase II study, which showed that neoadjuvant cemiplimab-rwlc in patients with stage II–IV (M0) resectable cutaneous squamous cell carcinoma is active and may enable function-preserving surgery in some cases (Abstract 789O).

Advertisement

Advertisement



Advertisement